Figure 1.
Figure 1. Cumulative incidence of hematologic malignancy. Cumulative incidence of hematologic malignancy among BRCA2 mutation carriers (14 patients) versus all other complementation groups in the IFAR (746 patients).

Cumulative incidence of hematologic malignancy. Cumulative incidence of hematologic malignancy among BRCA2 mutation carriers (14 patients) versus all other complementation groups in the IFAR (746 patients).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal